Thu May 22, 2014 8:11am EDT
<span id="articleText"/>(Reuters) - Isis Pharmaceuticals Inc said its experimental blood thinner was more effective than a commonly prescribed anticoagulant in patients undergoing total knee replacement surgery.
<span id="midArticle_0"/>The biotechnology company's stock rose about 2.8 percent in light trading before the bell on Thursday.
<span id="midArticle_1"/>Isis said patients treated with a 300 mg dose of the drug, ISIS-FXIRx, experienced a significantly lower incidence of blood clots in their veins, compared to patients given the approved anticoagulant, enoxaparin, in a mid-stage study.
<span id="midArticle_2"/>ISIS-FXIRx targets Factor XI, a clotting factor produced in the liver. High levels of Factor XI raises the risk of thrombosis, a condition where abnormal blood clot formation could lead to heart attacks and strokes.
<span id="midArticle_3"/>The trial was evaluating 200 mg and 300 mg doses of Isis's treatment against enoxaparin in 300 patients.
<span id="midArticle_4"/>The company said the 200 mg dose did not show any significant benefit over enoxaparin.
<span id="midArticle_5"/>The Carlsbad, California-based company's shares closed at $23.20 on the Nasdaq on Wednesday.
<span id="midArticle_6"/><span id="midArticle_7"/>(Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)
<span id="midArticle_8"/>
<span id="articleText"/>(Reuters) - Isis Pharmaceuticals Inc said its experimental blood thinner was more effective than a commonly prescribed anticoagulant in patients undergoing total knee replacement surgery.
<span id="midArticle_0"/>The biotechnology company's stock rose about 2.8 percent in light trading before the bell on Thursday.
<span id="midArticle_1"/>Isis said patients treated with a 300 mg dose of the drug, ISIS-FXIRx, experienced a significantly lower incidence of blood clots in their veins, compared to patients given the approved anticoagulant, enoxaparin, in a mid-stage study.
<span id="midArticle_2"/>ISIS-FXIRx targets Factor XI, a clotting factor produced in the liver. High levels of Factor XI raises the risk of thrombosis, a condition where abnormal blood clot formation could lead to heart attacks and strokes.
<span id="midArticle_3"/>The trial was evaluating 200 mg and 300 mg doses of Isis's treatment against enoxaparin in 300 patients.
<span id="midArticle_4"/>The company said the 200 mg dose did not show any significant benefit over enoxaparin.
<span id="midArticle_5"/>The Carlsbad, California-based company's shares closed at $23.20 on the Nasdaq on Wednesday.
<span id="midArticle_6"/><span id="midArticle_7"/>(Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)
<span id="midArticle_8"/>
- Link this
- Share this
- Digg this
- Reprints
via Smart Health Shop Forum http://ift.tt/1n4PrY8
No comments:
Post a Comment